Wave Life Sciences Ltd.(WVE)Earnings, Financials & Key RatiosWave Life Sciences Ltd. (WVE) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a strong liquidity position of $544.6M, the lack of consistent revenue and the high risk of clinical milestone dependency warrant a cautious approach until operational scale is achieved.
Wave Life Sciences Ltd. (WVE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Wave Life Sciences Ltd. (WVE) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.13vs $0.34+61.8% | $38Mvs $8M+352.6% |
| Q1 2026 | Feb 26, 2026 | $0.30vs $0.28-7.1% | $17Mvs $16M+7.4% |
| Q4 2025 | Nov 10, 2025 | $0.32vs $0.30-6.7% | $8Mvs $16M-53.5% |
| Q3 2025 | Jul 30, 2025 | $0.31vs $0.29-6.9% | $9Mvs $10M-11.7% |
Recent stock market news and headlines for Wave Life Sciences Ltd. (WVE)
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Key metrics vs top competitors for Wave Life Sciences Ltd. (WVE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.38 | $1.23B | -5.27 | -60.55% | -478.33% | -55.56% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Wave Life Sciences Ltd. (WVE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Wave Life Sciences Ltd. (WVE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 28, 2026·SEC
Apr 21, 2026·SEC
Apr 15, 2026·SEC
Get notified when WVE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Wave Life Sciences Ltd. (WVE) stock FAQ — growth, dividends, profitability & financials explained
Wave Life Sciences Ltd. (WVE) reported $71.8M in revenue for fiscal year 2025.
Wave Life Sciences Ltd. (WVE) saw revenue decline by 60.5% over the past year.
Wave Life Sciences Ltd. (WVE) reported a net loss of $183.6M for fiscal year 2025.
Wave Life Sciences Ltd. (WVE) has a return on equity (ROE) of -55.6%. Negative ROE indicates the company is unprofitable.
Wave Life Sciences Ltd. (WVE) had negative free cash flow of $183.3M in fiscal year 2025, likely due to heavy capital investments.
